Showing 8871-8880 of 9282 results for "".
- Suneva Medical Introduces Regenica Recovery Gelhttps://practicaldermatology.com/news/suneva-medical-introduces-regenica-recovery-gel/2458983/Suneva Medical, Inc. introduced Regenica® Recovery Gel, a new addition to the Regenica® skin care system, during the American Academy of Dermatology Annual Meeting. Regenica® Recovery Gel is a soothing balm that is specially formulated to help quickly heal damaged skin. It infuses Mul
- Nanotechnology Study Offers New Direction for Wound Healing Therapyhttps://practicaldermatology.com/news/nanotechnology-study-offers-new-direction-for-wound-healing-therapy/2458991/A novel nanoparticle technology appears to promote wound healing and has led researchers to a new therapeutic target for wound healing, a new study says. Writing in Journal of Investigat
- Promius Pharma, LLC to Market, Distribute Trianex 0.05%https://practicaldermatology.com/news/promius-pharma-llc-to-market-distribute-trianex-005/2458997/Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of
- FDA Clears New 532 nm Laser Delivery System for PicoSure from Cynosurehttps://practicaldermatology.com/news/fda-clears-new-532-nm-laser-delivery-system-for-picosure-from-cynosure/2459001/Cynosure, Inc. received FDA 510(k) clearance of its new 532 nm Laser Delivery System for PicoSure®, creating a powerful, dual-wavelength laser system for removing tattoos of all colors in fewer treatments. PicoSure is widely recognized for its technology
- Mikael Svensson Named Sr. VP of Sales/Marketing for Revision Skincarehttps://practicaldermatology.com/news/mikael-svensson-named-sr-vp-of-salesmarketing-for-revision-skincare/2459010/Revision Skincare appointed Mikael Svensson to the position of Senior Vice President of Sales and Marketing. In this new role, Mr. Svensson will oversee all Sales and Marketing activities, which include the strategic direction and leadership of Revis
- Oculus Innovative Sciences Launches IntraDerm Pharmaceuticals, New Dermatology Divisionhttps://practicaldermatology.com/news/oculus-innovative-sciences-launches-intraderm-pharmaceuticals-new-dermatology-division/2459028/Oculus Innovative Sciences, Inc., a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, has launched a
- Chromogenex Releases Regenlite Transformhttps://practicaldermatology.com/news/chromogenex-releases-regenlite-transform/2459042/The latest addition to the Chromogenex family, Regenlite Transform is now available. It is specifically designed for managing inflammatory skin conditions without any discomfort, downtime or residual cell necrosis, the company says. A pure 585nm laser offers 300% more absorption in Oxyhae
- Sienna Labs Obtains Fifth Patent Relating to Use of Plasmonic Nanoparticles in Treatment of Sebaceous Glands and Hairhttps://practicaldermatology.com/news/sienna-labs-obtains-fifth-patent-relating-to-use-of-plasmonic-nanoparticles-in-treatment-of-sebaceous-glands-and-hair/2459048/Siienna Labs was issued US Patent No. 8,895,071 covering, among other aspects, methods of using the company's plasmonic nanoparticle platform for localizing thermal damage to sebaceous glands and hair, a key mechanism for their investigational acne treatment and hair removal indications.
- The Cetaphil Brand Launches New Cetaphil Baby Linehttps://practicaldermatology.com/news/the-cetaphil-brand-launches-new-cetaphil-baby-line/2459050/Galderma Laboratories, L.P., makers of Cetaphil, launched Cetaphil Baby, a line designed with babies and parents in mind. Cetaphil Baby is formulated with ingredients like organic calendula, almond oil and sunflower oil to soothe sensitive and irritated skin. All Cetaphil Baby products are
- PV-10 Data Published; Phase 3 Protocol Publishedhttps://practicaldermatology.com/news/20141121-pv-10_data_published_phase_3_protocol_published/2459054/Phase II data for PV-10 (Provectus Biopharmaceuticals, Inc.), presented at scientific meetings this fall, were published in Annals of Surgical Oncology in October. In the 80-subject study, the best overall response rate for target lesions was 51 percent, and the complete response rate was 26 percent